Study guide
14.3 Metabolism & Elimination
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
14.3 Metabolism & Elimination
Key Takeaways Explain This Topic AI
Phase I reactions (mostly CYP450 oxidation) introduce reactive groups; phase II conjugations (glucuronidation, sulfation, acetylation, glutathione) almost always inactivate and polarize the drug
Know the big five isoforms: grapefruit juice and azoles inhibit CYP3A4; rifampicin, carbamazepine, phenytoin and St John's Wort are broad inducers; smoking induces CYP1A2
Prodrugs need metabolism to work: codeine→morphine (CYP2D6), clopidogrel (CYP2C19), levodopa→dopamine, valaciclovir→aciclovir
Induction takes days to weeks (new enzyme synthesis) and carbamazepine autoinduces itself; inhibition is rapid but mechanism-based inhibitors outlast their own plasma presence
CL = k × Vd = CL_hepatic + CL_renal; high-extraction drugs (lidocaine, propranolol) are flow-limited, low-extraction drugs (warfarin, phenytoin, theophylline) are capacity-limited
Last updated: August 2026
Phase I and Phase II Metabolism
Biotransformation converts lipophilic drugs into more polar, readily excreted products, mainly in the liver.
Phase I reactions — oxidation, reduction and hydrolysis — introduce or expose a reactive group. Most are catalysed by the cytochrome P450 (CYP450) superfamily in hepatocyte smooth endoplasmic reticulum. Products may be active, inactive or occasionally toxic (e.g., paracetamol oxidation to the hepatotoxic metabolite NAPQI).
Phase II reactions — conjugation of the drug or its phase I metabolite with a large polar group: glucuronidation (the most common), sulfation , acetylation , methylation and glutathione conjugation. Products are almost always inactive and water-soluble. Acetylation shows a clinically important polymorphism: slow acetylators (low NAT2 activity) are prone to isoniazid-induced neuropathy and to drug-induced lupus from hydralazine and procainamide.
Major CYP450 isoforms — the exam table
Isoform Representative substrates Inhibitors Inducers
CYP3A4 Simvastatin, felodipine, midazolam, ciclosporin, many macrolides Azole antifungals, ritonavir, erythro-/clarithromycin, grapefruit juice (intestinal) Rifampicin, carbamazepine, phenytoin, St John's Wort
CYP2D6 Metoprolol, codeine (activation), tramadol, many antidepressants and antipsychotics Fluoxetine, paroxetine, bupropion No clinically important inducers; genetic polymorphism (poor vs ultrarapid metabolizers) dominates
CYP2C9 S-warfarin, phenytoin, NSAIDs, sulfonylureas Fluconazole, metronidazole, amiodarone Rifampicin
CYP2C19 Clopidogrel (activation), proton pump inhibitors, some antidepressants Omeprazole, fluvoxamine Rifampicin
CYP1A2 Theophylline, caffeine, clozapine, olanzapine Ciprofloxacin, fluvoxamine Tobacco smoke (polycyclic hydrocarbons), carbamazepine
Memory hooks: grapefruit juice and azoles inhibit 3A4 (substrate levels rise ); rifampicin, carbamazepine, phenytoin and St John's Wort are broad inducers (substrate levels fall — the mechanism behind oral contraceptive and warfarin failure with rifampicin); smoking induces 1A2 , so smokers need higher theophylline and clozapine doses, and quitting smoking on an unchanged dose can cause toxicity.
Prodrugs
Prodrugs are inactive (or much less active) compounds that require metabolism for activation:
Codeine → morphine by CYP2D6. Poor metabolizers get little analgesia; ultrarapid metabolizers can generate dangerous morphine levels (fatal respiratory depression has been reported in breastfed infants of ultrarapid-metabolizer mothers).
Clopidogrel → active thiol metabolite, largely via CYP2C19. Poor metabolizers — and patients co-prescribed CYP2C19 inhibitors such as omeprazole — get a blunted antiplatelet effect.
Levodopa crosses the blood-brain barrier (unlike dopamine) and is decarboxylated to dopamine centrally; co-formulated carbidopa or benserazide blocks its peripheral conversion.
Valaciclovir → aciclovir by hydrolysis, giving roughly 3–5 times the oral bioavailability of aciclovir itself.
Enzyme Induction versus Inhibition — the time course
Induction requires synthesis of new enzyme protein, so onset and offset are slow — days to weeks . Rifampicin takes about a week to reach full effect and two or more weeks to wear off after stopping. Carbamazepine autoinduces its own metabolism : concentrations fall over the first 2–4 weeks on a fixed dose, so it is started low and titrated upwards.
Inhibition is usually rapid — as soon as the inhibitor reaches the enzyme. Clarithromycin can raise simvastatin levels within days (rhabdomyolysis risk), and grapefruit juice acts on intestinal CYP3A4 with the first glass. Mechanism-based (irreversible) inhibitors — macrolides, grapefruit juice — persist until new enzyme is synthesized, so their effect outlasts the inhibitor's presence in plasma.
Clinical reflex for the exam: when an interacting drug is started or stopped, ask which way the substrate level moves and how fast . Induction questions are the classic trap because the interaction only appears after a delay — warfarin control, for example, collapses a week or two after rifampicin is begun, not on day one.
Renal Elimination
Three processes determine renal clearance:
Glomerular filtration — free (unbound) drug of low molecular weight is filtered; protein-bound drug is not. Filtration tracks GFR (~120 mL/min in healthy young adults), which is why renally cleared drugs need dose adjustment when eGFR falls.
Active tubular secretion — organic anion (OAT) and cation (OCT) transporters in the proximal tubule actively secrete drugs regardless of protein binding. Secretion is saturable and competitive: probenecid blocks penicillin secretion (used historically to prolong penicillin action) and raises levels of methotrexate and many antivirals.
Passive tubular reabsorption — lipophilic, unionized drug is reabsorbed from the tubule. Because reabsorption is pH-dependent, manipulating urine pH changes elimination of weak electrolytes: urinary alkalinization with sodium bicarbonate ionizes salicylate (a weak acid) in the tubule, trapping it in urine and accelerating elimination in aspirin overdose — ion trapping in action.
Biliary Excretion and Enterohepatic Recycling
Larger, polar drugs and conjugated metabolites (often glucuronides, molecular weight above roughly 300–500) are excreted into bile. Gut bacteria can hydrolyse the conjugates, releasing active drug that is reabsorbed — enterohepatic recycling — which prolongs half-life and can produce a second plasma peak. Examples: ezetimibe (recycling sustains its cholesterol-lowering effect), mycophenolate (second peak at ~6–12 hours), and some oral contraceptive steroids (the classic teaching that broad-spectrum antibiotics reduce enterohepatic recycling and contraceptive efficacy — the evidence is weak, but it remains a standard exam point).
Clearance and Extraction Ratio
Clearance (CL) is the volume of plasma irreversibly cleared of drug per unit time:
CL = k × Vd , where k = 0.693 ÷ t½; and CL_total = CL_hepatic + CL_renal (+ other minor routes)
Worked example: a drug with t½ = 4 h and Vd = 40 L:
- k = 0.693 ÷ 4 = 0.173 h⁻¹
- CL = 0.173 × 40 ≈ 6.9 L/h
Clearance (not half-life) sets the maintenance dose: maintenance dose rate = CL × target Css ÷ F — for a target steady-state concentration of 15 mg/L and F = 1, that is 6.9 × 15 ≈ 104 mg/h.
The hepatic extraction ratio (E) predicts what controls hepatic clearance:
High-extraction drugs (E > 0.7) — propranolol, lidocaine, morphine, GTN: clearance is flow-limited (depends on hepatic blood flow), shows a large first-pass effect, and falls sharply with portosystemic shunting or hepatic congestion.
Low-extraction drugs (E < 0.3) — warfarin, phenytoin, theophylline, diazepam: clearance is capacity-limited (depends on enzyme activity and free fraction), so it is sensitive to enzyme induction, inhibition and hypoalbuminemia.